Monalizumab
- Generic Name
- Monalizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1228763-95-8
- Unique Ingredient Identifier
- 3ZXZ2V0588
- Background
Monalizumab has been used in trials studying the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 383
- Registration Number
- NCT02671435
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 22
- Registration Number
- NCT02557516
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath